Hormone Changes in Women With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Receiving Erlotinib
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00602433|
Recruitment Status : Completed
First Posted : January 28, 2008
Last Update Posted : April 15, 2011
Studying samples of blood in the laboratory from patients receiving erlotinib may help doctors learn more about the effects of erlotinib on hormone levels.
This clinical trial is looking at hormone changes in women with stage IIIB or stage IV non-small cell lung cancer receiving erlotinib.
|Condition or disease|
|Advanced Nonsmall Cell Lung Cancer|
|Study Type :||Observational|
|Actual Enrollment :||10 participants|
|Official Title:||Evaluation of Hormonal Changes in Women on Erlotinib Therapy|
|Study Start Date :||December 2007|
|Actual Primary Completion Date :||August 2009|
|Actual Study Completion Date :||August 2009|
questionnaire and laboratory biomarker analysis
Subjects with advanced non-small cell lung cancer and take erlotinib as part of their anticancer therapy for at least 3 months. Subjects have had some changes in hair growth, acne or menses (periods) that might be a side effect of erlotinib. Subjects will complete a questionnaire and blood collected for biomarker analysis.
- Presence of hyperandrogenemia [ Time Frame: One approximate 30 minute visit ]We will determine if hyperandrogenemia is present in women with nonsmall cell lung cancer who are taking erlotinib.
- Dermatologic manifestations [ Time Frame: One approximate 30 minute visit ]We will describe the dermatologic manifestations of erlotinib in women
- Changes in body habitus and patterns of hair loss [ Time Frame: One approximate 30 minute visit ]We will describe changes in body habitus and patterns of hair loss from women on erlotinib.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00602433
|United States, Illinois|
|Northwestern University, Northwestern Medical Faculty Foundation|
|Chicago, Illinois, United States, 60611-3013|
|Principal Investigator:||Jyoti D. Patel, MD||Northwestern University|